North America Pulmonary Arterial Hypertension Market Size & Outlook
North America pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
North America pulmonary arterial hypertension market highlights
- The North America pulmonary arterial hypertension market generated a revenue of USD 3,220.9 million in 2023.
- The market is expected to grow at a CAGR of 4.9% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 3,220.9 million |
| Market revenue in 2030 | USD 4,504.4 million |
| Growth rate | 4.9% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, North America region accounted for 43.7% of the global pulmonary arterial hypertension market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,501.9 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.42% in 2023. Horizon Databook has segmented the North America pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
North America accounted for largest share about 57.7% of global PAH market in 2020. Developed healthcare infrastructure in U.S. enabled access to advanced therapeutics which contributed to the growth of this region. Moreover, availability of reimbursement on PAH therapies supported the growth of North American PAH market.
Growing awareness, high diagnosis rate and supportive government initiatives governed the growth of this region. Sedentary lifestyle habits such as smoking, alcohol and junk food are vital risk factors for development of PAH.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America pulmonary arterial hypertension market size, by country, 2018-2030 (US$M)
North America Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
